Lurasidone is indicated for the treatment of adult
patients with major depressive episodes associated with bipolar I disorder
(bipolar depression). Bipolar depression is characterized by debilitating moodchanges, by one or more manic or mixed episodes; often, individuals also
experience at least one major depressive episode.
The objective of this study was to establish the
Bioequivalence of two formulations containing Irbesartan 300 mg tablets bycomparing its bioavailability after a single dose between the Test product
produced by Lafrancol S.A. (Colombia) and the Reference product, Latuda®,
produced by Sunovion.
No comments:
Post a Comment